TARO Overview
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading chart...
The current price of TARO is 0 USD — it has increased 0
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Wall Street analysts forecast TARO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TARO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Taro Pharmaceutical Industries Ltd revenue for the last quarter amounts to 164.94M USD, increased 12.52
Taro Pharmaceutical Industries Ltd. EPS for the last quarter amounts to 0.40 USD, increased 122.22
Taro Pharmaceutical Industries Ltd (TARO) has 1554 emplpoyees as of June 01 2026.
Today TARO has the market capitalization of 1.61B USD.
